Home / Provider Reviews / Oak Longevity Review
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Prices verified October 15, 2026·Methodology v4.1

Oak Longevity review (2026): pricing, programs, pros and cons

Direct answer · October 15, 2026

As of October 15, 2026, Oak Longevity publishes two different starting prices for its GLP-1 weight-loss program, “from $119/mo” on its homepage and “start at $190/month” on its weight-loss page, so we list it without a rank or a price until the pages agree.

Oak did not publish a tirzepatide-specific price; its site is oaklovesyou.com.

Verdict

Oak Longevity (oaklovesyou.com; oaklongevity.com returned a 404) runs weight-loss, longevity and ED programs. On October 15 its homepage said “Prescription weight loss from $119/mo”, while its own weight-loss page said “Oak’s weight loss programs start at $190/month” with “no hidden membership fees” and free shipping. A $71 gap between two pages of the same site is too wide to pick one, so we do not rank Oak on price. Neither page gave a tirzepatide price.

The longevity side is priced more clearly but needs care. NAD+ injections were $175 a month, “regularly $199”. Sermorelin and tesamorelin are priced only after an assessment. Oak describes tesamorelin as something a provider “may consider to support healthy body composition”; the only FDA-approved tesamorelin, Egrifta WR, is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy and is “not indicated for weight loss management”. NAD+ has no FDA-approved drug form.

Oak’s footer says “Compounded medications are not FDA approved.” We did not find named pharmacies or lab terms. This site has not yet scored Oak Longevity on methodology v4.1 (v4.1 score pending).

Snapshot

Oak Longevity snapshot · each field with its source and read date · status as of October 15, 2026
FieldWhat the provider’s page saysSource · read dateStatus
GLP-1 weight loss (homepage)“from $119/mo”oaklovesyou.com · October 15, 2026Verified
GLP-1 weight loss (program page)“start at $190/month”oaklovesyou.com/weightloss · October 15, 2026Verified
Rankable priceNone while the pages conflictOctober 15, 2026No published price
TirzepatideNot pricedoaklovesyou.com · October 15, 2026No published price
Membership · shipping“no hidden membership fees” · freeoaklovesyou.com/weightloss · October 15, 2026Verified
NAD+ injections$175 a month, “regularly $199”oaklovesyou.com/longevity · October 15, 2026Verified
Sermorelin · tesamorelinPriced after assessmentoaklovesyou.com/longevity · October 15, 2026No published price
ED treatment“from $60/mo”oaklovesyou.com · October 15, 2026Verified
PharmacyNot namedoaklovesyou.com · October 15, 2026Not disclosed

Pricing, October 15, 2026

Every figure below is a “from” or “start at” price; none states the plan length or dose behind it.

Oak Longevity prices · first-party pages on oaklovesyou.com · read October 15, 2026
ProgramPrice shownBasisSource · read date
GLP-1 weight loss$119 a month“from”, homepageoaklovesyou.com · October 15, 2026
GLP-1 weight loss (compounded semaglutide program)$190 a month“start at”, weight-loss pageoaklovesyou.com/weightloss · October 15, 2026
NAD+ injections$175 a monthPromotional; regularly $199oaklovesyou.com/longevity · October 15, 2026
Longevity (homepage card)$99 a month“from”oaklovesyou.com · October 15, 2026

What changed since our July 2026 review

The July 2026 figures below are kept only so you can see what moved. None of them is a current price.

Oak Longevity · July 2026 capture (superseded) vs October 15, 2026 read
ItemJuly 2026 (superseded)October 15, 2026
Semaglutide$133 a month on a multi-month plan$119 vs $190 “from” prices conflict
Tirzepatide$199 a month on a multi-month planNot priced
Month to month$167–$299Not printed
CaliforniaNot servedNot re-read
Compounding status · October 15, 2026Compounded tirzepatide and semaglutide are not FDA-approved, are not generics, and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. FDA’s shortage-era grace periods ended in 2025, so a pharmacy may compound them only for an individual patient whose prescriber documents a clinically significant difference from the approved drug. On September 18, 2026 FDA warned Empower Pharmacy that two of its GLP-1 products appeared to be essentially copies of approved drugs, and FDA has proposed keeping all three GLP-1s off the 503B bulks list (no final decision as of October 15). Background: is compounded GLP-1 legal?

Pros and cons

Pros

  • No hidden membership fees and free shipping (weight-loss page)
  • NAD+ price printed with its regular rate
  • Footer states that compounded drugs are not FDA-approved

Cons

  • Two conflicting GLP-1 starting prices
  • No tirzepatide price
  • Tesamorelin marketed for body composition, outside its approved use
  • Sermorelin and tesamorelin priced only after assessment
  • Pharmacies not named

Evidence ledger

Oak Longevity evidence ledger · claim, source, read date, status
ClaimSourceReadStatus
“from $119/mo” weight lossoaklovesyou.comOctober 15, 2026Verified
“start at $190/month” weight lossoaklovesyou.com/weightlossOctober 15, 2026Verified
NAD+ $175, regularly $199oaklovesyou.com/longevityOctober 15, 2026Verified
Egrifta WR indicationFDA label (BLA 022505)facts on file, October 15, 2026Verified

Limits. We read public pages and date each read. We have not audited pharmacy licences or measured patient outcomes, and we publish no user ratings. Confirm any price at checkout.

Alternatives to compare

Every program we track, with read dates, is in the GLP-1 pricing database.

Before you pay

  1. Find the ongoing price. Words like “first month”, “from”, “as low as” or “sale” mean the number beside them is not what month two costs.
  2. Add any membership and ask, in writing, the price at your maintenance dose.
  3. Ask what happens if you stop early on any plan longer than one month.
  4. Ask which pharmacy fills the prescription and whether it is a 503A or 503B facility, then check its licence with the state board of pharmacy.

Frequently asked questions

How much does Oak Longevity cost for weight loss?

Oak’s pages disagree. On October 15, 2026 its homepage said prescription weight loss “from $119/mo”, while its weight-loss page said programs “start at $190/month”, with no hidden membership fees and free shipping. Neither gave a tirzepatide price. Ask Oak for the price of your medication and dose in writing.

Why doesn’t this site rank Oak Longevity on price?

We rank a program on price only when its own pages give one consistent figure we can read. Oak’s homepage and weight-loss page showed $119 and $190 on the same day, so we list Oak without a price rank until they agree.

How much is NAD+ at Oak Longevity?

On October 15, 2026 Oak’s longevity page listed NAD+ injections at $175 a month, “regularly $199”. There is no FDA-approved NAD+ drug; NAD sits in Category 1 of FDA’s interim compounding policy, which is enforcement discretion, not approval. That status says nothing about whether NAD+ injections work; human evidence comes from small, short studies.

Is tesamorelin approved for weight loss?

No. Tesamorelin’s only FDA-approved product, Egrifta WR, reduces excess abdominal fat in adults with HIV and lipodystrophy, and its label says it is not indicated for weight-loss management. Oak describes it as supporting “healthy body composition”, which is off-label. WADA also prohibits tesamorelin in sport.

Sources

  1. Oak Longevity — home page (read October 15, 2026)
  2. Oak Longevity — weight loss (read October 15, 2026)
  3. Oak Longevity — longevity (read October 15, 2026)
  4. NexLife — compounded tirzepatide plans (read October 15, 2026)
  5. My Peptide Information — GLP-1 pricing database (October 15, 2026 index: 28 tirzepatide and 22 semaglutide programs)

Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed ByDr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.